Divergent Kinetics Differentiate the Mechanism of Action of Two HDAC Inhibitors
详细信息 查看全文
- 作者：Astrid M. Kral ; Nicole Ozerova ; Joshua Close ; Joon Jung ; Melissa Chenard ; Judith Fleming ; Brian B. Haines ; Paul Harrington ; John Maclean ; Thomas A. Miller ; Paul Secrist ; Hongmei Wang ; Richard W. Heidebrecht ; Jr.
- 刊名：Biochemistry
- 出版年：2014
- 出版时间：February 4, 2014
- 年：2014
- 卷：53
- 期：4
- 页码：725-734
- 全文大小：609K
- ISSN：1520-4995
文摘
Histone deacetylases (HDACs) play diverse roles in many diseases including cancer, sarcopenia, and Alzheimer鈥檚. Different isoforms of HDACs appear to play disparate roles in the cell and are associated with specific diseases; as such, a substantial effort has been made to develop isoform-selective HDAC inhibitors. Our group focused on developing HDAC1/HDAC2-specific inhibitors as a cancer therapeutic. In the course of characterizing the mechanism of inhibition of a novel HDAC1/2-selective inhibitor, it was determined that it did not exhibit classical Michaelis鈥揗enten kinetic behavior; this result is in contrast to the seminal HDAC inhibitor SAHA. Enzymatic assays, along with a newly developed binding assay, were used to determine the rates of binding and the affinities of both the HDAC1/2-selective inhibitor and SAHA. The mechanism of action studies identified a potential conformational change required for optimal binding by the selective inhibitor. A model of this putative conformational change is proposed.